US
Overview
Ugur Sahin is a oncology specialist at BioNTech. Based in Turkey.
For Patients
- Pioneered the BNT162b2 mRNA COVID-19 vaccine, a technique still used by doctors worldwide
- Research is cited 32K+ times by other doctors and scientists, indicating significant influence on medical research
- Currently at BioNTech in Mainz, Turkey
Biography
Ugur Sahin is a Turkish-German oncologist and immunologist who co-founded BioNTech and co-developed the Pfizer-BioNTech COVID-19 mRNA vaccine, the first mRNA vaccine authorized worldwide.
Affiliations & Institutions
Research Impact
10 Publications
31,795 Total Citations
10K+ Citation Milestone
Publication Timeline
Published In
New England Journal of MedicineNatureNature Reviews Drug DiscoveryProceedings of the National Academy of Sciences
Key Publications
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
mRNA-based therapeutics — developing a new class of drugs
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Areas of Expertise
Pioneering Techniques
Medical Specialties
Clinical Knowledge & Procedures
Legacy Timeline
The life and contributions of Ugur Sahin
2008
Co-founded BioNTech
2020
Developed BNT162b2 COVID-19 vaccine
Created the first authorized mRNA vaccine in partnership with Pfizer